Capsule Summary Slidesets

Share

Program Content

Activities

  • Weight Change With DOR
    Low Weight Gain Over 96 Wks in Treatment-Naive Patients Initiating ART With Doravirine
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 18, 2019

  • DISCOVER
    DISCOVER: Renal Parameters and BMD Improved With FTC/TAF vs FTC/TDF for HIV PrEP at Wk 48
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 19, 2019

  • PrEP in US Metropolitan Areas
    Increased PrEP Uptake in US Metropolitan Statistical Areas During 2012-2017 Associated With Significant Reduction in New HIV Diagnoses Rate
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 29, 2019

  • LATTE
    LATTE: Durable Viral Suppression With Oral Cabotegravir + Rilpivirine Maintenance Therapy Through Wk 312
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 18, 2019

  • GEMINI
    GEMINI-1 and -2: Subgroup Analyses Consistent With Overall Safety and Efficacy Findings for DTG + 3TC in ART-Naive Adults at Wk 96
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 31, 2019

  • RAL Safety in Pregnancy
    No Increase in Adverse Birth Outcomes Following Exposure to Raltegravir in Pregnancy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 18, 2019

  • DIAMOND
    DIAMOND: High Virologic Suppression Rates Achieved Following Rapid Initiation of DRV/COBI/FTC/TAF Regardless of Baseline HIV-1 RNA Level or CD4+ Cell Count
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 29, 2019

  • PrEP BMD Study
    Longitudinal Cohort Study Demonstrates Notable Rate of > 3% BMD Loss Over 2 Yrs Among MSM Receiving TDF-Based PrEP
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 19, 2019

  • TANGO Subgroup Analysis
    TANGO: Switch to DTG/3TC Maintains Virologic Suppression at Wk 48 Across Patient Demographics and Baseline Third Agent Classes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 08, 2019

  • BIC/FTC/TAF in Women
    BIC/FTC/TAF Safe and Efficacious in Women and Girls Across 5 Phase II/III Clinical Trials
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 20, 2019

Provided by

ProCE Banner

Supporters

Gilead

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare